Showing results (111-120 of 618) with videos related to
Sort By:
Pageof 62
Expert Opinion on Investigational Drugs|June 25, 2009
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectivesDavid P Samuel, Patrick Y Wen, Mark W KieranNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 22, 2017
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical TrialsBenjamin M Ellingson, Patrick Y Wen, Timothy F CloughesyCancer Journal (Sudbury, Mass.)|September 27, 2021
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and ImmunotherapiesBenjamin M Ellingson, Patrick Y Wen, Timothy F CloughesyJournal of Neuro-Oncology|October 8, 2024
Clinical trial design for novel targeted agents in neuro-oncologyMary Jane Lim-Fat, Katrina Roberto, Patrick Y WenExpert Review of Anticancer Therapy|April 27, 2013
Enhancing radiation therapy for patients with glioblastomaBrian M Alexander, Keith L Ligon, Patrick Y WenGlia|February 26, 2011
Signal transduction inhibitors and antiangiogenic therapies for malignant gliomaIngo K Mellinghoff, Andrew B Lassman, Patrick Y WenNeuro-Oncology|October 25, 2014
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challengesDavid A Reardon, Patrick Y Wen, Ingo K MellinghoffInternational Journal of Radiation Oncology, Biology, Physics|June 3, 2008
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiformeJan Drappatz, Eric T Wong, David Schiff, et al.Neuro-Oncology|April 25, 2007
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adultsSantosh Kesari, David Schiff, Lisa Doherty, et al.Journal for Immunotherapy of Cancer|September 2, 2018
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two casesChristine A Garcia, Alex El-Ali, Tanya J Rath, et al.Pageof 62